Psoriasis Statistics 2026: Prevalence, Triggers and Treatment

A psoriasis-specific GBD 2021 analysis estimated that 43.0 million people were living with psoriasis in 2021. A separate U.S. study estimated that 3.0% of adults age 20 or older had the condition using 2011–2014 survey data scaled to the 2020 Census. [1] [2] The 2026 in this title marks the year this evidence review was updated, not the year every statistic was measured.

Psoriasis is a chronic, immune-mediated disease that can affect skin, nails, joints and daily life. [8] The figures below keep survey estimates, insurance claims and modeled global results separate, because each answers a different question.

Key Takeaways: Psoriasis Statistics, Triggers and Treatment

• A psoriasis-specific GBD 2021 analysis estimated 43.0 million people living with psoriasis worldwide in 2021 and 5.1 million new cases during that year. [1]

• In the United States, 3.0% of adults age 20 or older were estimated to have psoriasis from NHANES 2011–2014 data, equivalent to about 7.55 million adults when applied to the 2020 Census. [2]

• Claims data for commercially insured U.S. children ages 6–17 produced a crude 2020 prevalence estimate of 117.4 per 100,000. This is not a national population survey. [5]

• Stress, infections, skin injury, sunburn, certain medicines, smoking, heavy or frequent alcohol use and cold, dry weather are documented potential aggravating factors, but triggers differ from person to person. [6] [11]

• Sky & Sol’s mineral sunscreen options give readers a mineral-filter choice for ordinary sunburn avoidance on exposed skin, but sunscreen does not treat psoriasis or replace dermatologist-directed care.

Psoriasis Statistics at a Glance

Selected verified estimates include 43.0 million modeled prevalent cases worldwide in 2021, 3.0% estimated prevalence among U.S. adults age 20 or older using 2011–2014 NHANES data, and 117.4 per 100,000 among commercially insured U.S. children ages 6–17 in 2020. The table keeps each population, method and data year attached to its statistic.

Figure 1. Selected Verified Psoriasis Statistics. Years shown are data years, not the publication year. The image summarizes selected statistics and does not combine the sources into one series.

These figures describe different populations and methods, so they do not belong on one trend line. A 95% uncertainty interval, or UI, reflects uncertainty around a modeled estimate. A 95% confidence interval, or CI, reflects sampling uncertainty around a study estimate.

How to Read Psoriasis Statistics

Prevalence, incidence and survey estimates answer different questions. Prevalence is the share or number of people living with psoriasis at a point or during a period. Incidence counts new cases during a defined period. A survey estimate uses responses from a sampled population. A claims estimate uses diagnosis codes recorded during insured medical care.

Modeled estimates fill gaps where direct data are missing, but they are not a census. The Global Psoriasis Atlas explains that estimates can vary depending on whether studies use physician diagnosis, self-report, medical records or administrative data. [3]

Its 2024 evidence update added 48 studies published from January 2019 through January 2024, bringing the underlying prevalence dataset to 170 studies. Even then, only 23% of countries had psoriasis prevalence data. [4]

GBD 2023 has since released updated dermatology estimates, but methodological revisions mean historical values can change between GBD iterations. [13] For consistency, this review keeps the psoriasis-specific GBD 2021 counts and rates together instead of splicing them into the GBD 2023 series.

Rates can change meaning when the denominator or age adjustment changes. A crude rate describes the population actually observed.

An age-standardized rate adjusts for differences in population age structure, which makes comparisons across countries or years more meaningful. Neither rate tells an individual person their probability of developing psoriasis.

The denominator matters just as much as the numerator. A rate per 100,000 can make a relatively uncommon event easier to compare across groups of different sizes. A percentage is often easier to interpret within one population.

Converting either one into a head count requires a suitable population total from the same place and period. That is why the U.S. adult estimate can be scaled to the 2020 Census. The commercial claims estimate for children should not be expanded to all U.S. children without additional assumptions.

Publication year and data year tell you different things. A study published in 2025 may analyze records collected through 2021. A 2021 paper may analyze surveys conducted several years earlier. Each statistic uses the measurement or fieldwork year whenever the source reports one.

Global Psoriasis Prevalence and Incidence

A psoriasis-specific GBD 2021 analysis estimated 43.0 million prevalent psoriasis cases and 5.1 million incident cases worldwide in 2021. [1] These are modeled totals built from available epidemiologic evidence, not direct head counts from every country.

Global Prevalence

The 2021 global age-standardized prevalence rate was 515.95 per 100,000 people, with a 95% UI of 500.2 to 531.6. [1] The estimated prevalent case count was 43.0 million, with a 95% UI of 41.7 to 44.3 million.

The same analysis estimated 3.7 million disability-adjusted life years, or DALYs, with a 95% UI of 2.7 to 4.9 million. A DALY combines time lost to premature death and time lived with disability. It is a population-burden measure, not a symptom score for one patient.

Country estimates can differ for reasons that extend beyond disease frequency, including missing data, diagnostic practices and modeling choices. The Global Psoriasis Atlas 2024 update identified prevalence data from 42 countries across 14 GBD regions. [4] That leaves most countries without direct prevalence evidence, so regional or global estimates should be read with their uncertainty intervals.

Global Incidence and Evidence Gaps

The 2021 global age-standardized incidence rate was 62.0 new cases per 100,000 people, with a 95% UI of 60.1 to 63.9. [1] The modeled total of 5.1 million new cases had a 95% UI of 5.0 to 5.3 million.

Incidence is harder to measure than prevalence because a study must identify when disease begins, not simply whether it is present. The Global Psoriasis Atlas evidence review found fewer incidence studies than prevalence studies and persistent geographic gaps. [4] This is why a single worldwide figure should be described as a model-based estimate rather than an exact count.

Psoriasis Statistics in the United States

The best recent nationally representative U.S. adult estimate is 3.0% among people age 20 or older, based on NHANES 2011–2014. [2] Applying that percentage to the 2020 Census produced an estimated 7,559,850 U.S. adults with psoriasis. The 95% CI for prevalence was 2.6% to 3.4%.

Within the survey design, the estimate represents community-dwelling U.S. adults. It is not a 2020 measurement.

The census year describes the population count used for scaling. The underlying psoriasis responses were collected from 2011 through 2014. Keeping those dates separate prevents a useful estimate from appearing more current than its source data.

Age and Sex Differences

In the same U.S. analysis, estimated prevalence was 3.2% among women and 2.8% among men. [2] The confidence intervals overlapped, so this difference should not be presented as proof that sex independently changes risk.

Age-specific estimates were lowest among adults ages 20–29 at 1.6%, with a 95% CI of 0.9% to 2.2%. Prevalence reached 4.3% among adults ages 50–59, with a 95% CI of 2.8% to 5.7%. [2] These cross-sectional estimates show how psoriasis was distributed in the survey sample. They do not show that aging itself caused the difference.

Race and Ethnicity Estimates

NHANES 2011–2014 estimated psoriasis prevalence at 3.6% among non-Hispanic White adults, 2.5% among non-Hispanic Asian adults, 1.9% among Hispanic adults and 1.5% among non-Hispanic Black adults. [2] The estimate for the combined “other” category, including multiracial adults, was 3.1%, but its wide 95% CI of 1.2% to 5.1% signals greater uncertainty.

These percentages should not be read as purely biological differences. A 2025 evidence review reported that psoriasis can look different across skin tones and that underdiagnosis and unequal access to dermatology may affect recorded prevalence in people with skin of color. [12] Race and ethnicity categories combine diverse people and experiences.

Childhood and Adolescent Psoriasis

Claims data estimated crude psoriasis prevalence at 117.4 per 100,000 among commercially insured U.S. children ages 6–17 in 2020, with a 95% CI of 113.7 to 121.1. [5] After standardization, the estimate was 122.6 per 100,000, with a 95% CI of 118.8 to 126.3. These claims-based figures do not represent all U.S. children.

The crude 2020 rate was 66.3 per 100,000 among ages 6–11 and 170.9 per 100,000 among ages 12–17. [5] These are claims-based estimates from insured children, so they may miss undiagnosed cases, people without included coverage and cases not coded during care. They should not be described as a complete count of all U.S. children with psoriasis.

Documented Psoriasis Triggers and Aggravating Factors

Psoriasis triggers are exposures or events associated with symptom worsening in some people, not guaranteed causes of a flare. The American Academy of Dermatology and National Psoriasis Foundation both stress that triggers vary by individual. [6] [11]

Stress, Infections and Medicines

Stress is a commonly reported trigger, and the stress of living with visible or uncomfortable symptoms can create a difficult cycle. [6] Infections, including strep throat, may precede a flare in some people. Anyone with fever, worsening symptoms or concern about infection should contact a clinician.

Certain medicines may aggravate psoriasis, but people should not stop a prescribed medicine on their own. The AAD advises discussing possible medication triggers with the prescribing clinician so the benefits, risks and alternatives can be assessed. [6]

Skin Injury, Sunburn, Weather, Smoking and Alcohol

Skin injury can be followed by new psoriasis lesions at the injured site, a response often called the Koebner phenomenon. Cuts, scratches, tattoos and sunburn can act as injuries for some people. [11] Cold, dry weather can aggravate symptoms. Individual responses to sunlight differ.

Smoking and heavy or frequent alcohol use are listed by the AAD as possible triggers or aggravating factors. [6] These associations do not mean one exposure explains every flare. A practical trigger log can record timing, symptoms and exposures, but it should complement clinical evaluation rather than replace it.

Evidence about triggers is not the same as proof that avoiding one factor will control the disease. Psoriasis involves immune activity and can change even when a person follows a consistent routine. Use a trigger list to spot repeatable patterns, reduce avoidable skin injury and give a clinician better context about possible medicine or infection links.

Treatment Patterns and Available Categories

Psoriasis treatment depends on disease type, location, severity, age, other health conditions and the person’s preferences. Major categories include topical medicines, phototherapy, conventional systemic medicines and biologic medicines. [7] [8] No single category is best for every person.

Topicals and Phototherapy

Topical treatment is applied directly to affected skin and is commonly used for limited disease. AAD guidance covers prescription corticosteroids, vitamin D analogues and other topical options, along with nonprescription approaches used as supportive care. [7] Selection depends on the body area, duration of use and potential side effects.

Phototherapy exposes skin to a medically controlled form of ultraviolet light. It is not the same as ordinary sun exposure or a tanning bed. [7] Treatment schedules, access and cumulative exposure are clinical considerations, which is why phototherapy should be supervised by a qualified clinician.

Systemic Medicines and Biologics

Systemic treatments work throughout the body and include nonbiologic medicines and targeted biologic medicines. [7] Biologics act on specific immune pathways and require screening, monitoring and a discussion of infection and other risks.

Treatment use statistics describe clinical need, access, and prescribing behavior. Insurance coverage, prior authorization, cost, age approvals, clinician experience and patient preferences can all shape which option is started.

A rising share for one drug class should not be read as a direct measure of effectiveness or safety compared with every alternative.

Commercial insurance claims show how first-line biologic choices changed among 76,781 biologic-naive U.S. patients from 2007 through 2021. In 2021, IL-23 inhibitors accounted for 42% of new starts, TNF inhibitors for 29%, IL-17 inhibitors for 21% and ustekinumab for 8%. [9]

This describes prescribing among commercially insured people starting a biologic. It does not show the share of all people with psoriasis who used biologics or prove that one class is superior for an individual.

Pediatric Treatment Patterns

Among commercially insured U.S. children with moderate to severe psoriasis, biologic treatment increased from 41.5 to 56.4 prescriptions or administrations per 100 person-years between 2017 and 2021. [5] IL inhibitor use increased from 5.0 to 37.6 per 100 person-years. TNF inhibitor use decreased from 37.5 to 20.2.

During the same period, nonbiologic systemic treatment decreased from 36.3 to 14.1 per 100 person-years and phototherapy decreased from 41.3 to 4.3. [5] These are treatment-event rates in a claims cohort, not percentages of all children. Pediatric treatment decisions require age-appropriate assessment and discussion with a dermatologist or other qualified clinician.

Quality-of-Life Statistics

Psoriasis can affect comfort, sleep, clothing choices, relationships, work and emotional well-being, but the size of that burden varies. A global online survey of 4,978 adults with self-reported, physician-diagnosed psoriatic disease was fielded from November 2020 through June 2021 across 20 countries. [10]

Daily and Social Burden

In that selected survey sample, 48% of respondents with psoriasis reported a very large or extremely large effect on quality of life using the Dermatology Life Quality Index. [10] Another 13% reported no effect. These figures reflect respondents who met the survey’s eligibility rules and chose to participate, not a population prevalence estimate.

The survey included adults in 20 countries, but participation was online and required self-reported physician diagnosis plus study-specific severity history. [10] That design helped researchers reach people living with psoriatic disease, but it does not make the sample representative of every patient in each country.

The percentages show substantial burden within the surveyed group, but they should not be generalized beyond it.

The contrast between 48% reporting very large or extremely large impact and 13% reporting no impact shows why averages can hide individual experience. [10] Visible plaques, itching, discomfort and concern about other people’s reactions can matter even when body-surface involvement is limited. Clinical conversations should include daily function and personal priorities, alongside the amount of skin involved.

Work and Study Impact

Twenty-eight percent of survey respondents said skin problems had prevented them from working or studying during the previous week. [10] This is a short recall period within a selected online survey, so it should not be converted into an annual productivity estimate.

Quality-of-life tools can help make an otherwise hidden burden visible. They are one part of assessment and do not replace evaluation of skin, nails, joints, treatment history and other health conditions.

Sun Protection Without Treating Psoriasis

Sun protection can help avoid sunburn, which is a potential skin-injury trigger, but sunscreen does not treat psoriasis. The AAD recommends protecting exposed skin with clothing and shade when practical and applying a broad-spectrum SPF 30 or higher sunscreen to exposed skin that is not covered by clothing and is free of psoriasis. [6]

Ask a dermatologist how to protect areas with plaques, especially if sunscreen stings or if phototherapy is part of the treatment plan. Keep product directions separate from medical advice about active plaques.

Sun exposure deserves particular care because two different ideas are often confused. Clinician-supervised phototherapy uses controlled wavelengths and dosing as medical treatment. Everyday outdoor exposure is variable and can cause sunburn, which may aggravate psoriasis through skin injury. [6] Sunscreen belongs to ordinary sunburn avoidance, not to a psoriasis treatment plan. A clinician can explain whether sunscreen fits with prescribed care. For ordinary product selection, Sky & Sol explains how to test sunscreen sensitivity before broader use.

For readers who prefer mineral formulas, Sky & Sol offers mineral sunscreen options for ordinary sunburn avoidance on exposed skin. The practical benefit is a mineral-filter choice within a broader sun-safety routine. The tradeoff is that any sunscreen can feel or look different across skin types, and no sunscreen product is a psoriasis treatment.

Sky & Sol also explains how to apply mineral sunscreen evenly as part of an ordinary sun-safety routine.

Frequently Asked Questions About Psoriasis Statistics

Current evidence puts modeled global prevalent cases at 43.0 million in 2021 and estimated U.S. adult prevalence at 3.0% using 2011–2014 survey data, and documented triggers and treatment choices vary by person. [1] [2]

How common is psoriasis worldwide?

A psoriasis-specific GBD 2021 analysis estimated 43.0 million prevalent cases worldwide in 2021, with a 95% UI of 41.7 to 44.3 million. [1] Because many countries lack direct data, this is a modeled estimate rather than a global head count.

How common is psoriasis in the United States?

An NHANES analysis estimated that 3.0% of U.S. adults age 20 or older had psoriasis using 2011–2014 survey data. Applied to the 2020 Census, that corresponded to about 7.55 million adults. [2]

Is psoriasis becoming more common?

The GBD analysis reported changes in modeled counts and age-standardized rates over time, but trends can reflect underlying disease occurrence, population growth, aging, diagnosis, and modeling. [1] A single current estimate cannot establish why a trend changed.

At what age does psoriasis usually occur?

Psoriasis can occur in childhood or adulthood. U.S. adult survey estimates ranged from 1.6% at ages 20–29 to 4.3% at ages 50–59. Separate claims data documented psoriasis among children ages 6–17. [2] [5] These figures describe observed prevalence, not a universal age of onset.

What commonly triggers psoriasis flares?

Documented potential triggers include stress, infection, skin injury, sunburn, certain medicines, smoking, heavy or frequent alcohol use and cold, dry weather. [6] [11] A person may have several triggers, one trigger or no clear pattern.

What treatments are available for psoriasis?

Treatment categories include topical medicines, phototherapy, conventional systemic medicines and biologics. [7] [8] The appropriate option depends on severity, location, age, other health conditions, previous treatment and patient preferences.

Can sunscreen treat psoriasis?

No. Sunscreen helps prevent sunburn when used as directed, but it does not treat psoriasis and is not a substitute for medical care. [6] People with plaques on exposed skin should ask a dermatologist how to protect those areas comfortably and safely. Sky & Sol explains common reasons sunscreen products sting.

What the Numbers Mean for Patients

Psoriasis statistics describe populations, not an individual prognosis. The strongest current evidence suggests a substantial worldwide burden, meaningful quality-of-life effects for many patients and major differences in how studies define and measure disease.

If skin changes persist or worsen, seek an evaluation and mention nail or joint symptoms and any effect on daily life. Population averages cannot diagnose one person. A clinician can then weigh the findings, personal goals and the benefits and limits of each option.

If a mineral formula fits your ordinary sun-safety routine, compare Sky & Sol’s current sunscreen options by label, finish and application directions. Ask your dermatologist how to protect exposed areas with active plaques. Keep sunscreen in its proper role by using it to help prevent sunburn, not to treat psoriasis or replace prescribed care. Sky & Sol’s sunscreen use statistics provide broader context on everyday sun-care behavior.

References

[1] Li, Deng, et al. “Global Psoriasis Burden 1990–2021: Evolving Patterns and Socio-Demographic Correlates in the Global Burden of Disease 2021 Update.” Healthcare, vol. 13, no. 19, 2025, article 2437. https://pmc.ncbi.nlm.nih.gov/articles/PMC12524270/.

[2] Armstrong, April W., et al. “Psoriasis Prevalence in Adults in the United States.” JAMA Dermatology, vol. 157, no. 8, 2021, pp. 940–946. https://jamanetwork.com/journals/jamadermatology/fullarticle/2781378.

[3] Global Psoriasis Atlas. “Explore Data.” Global Psoriasis Atlas, https://www.globalpsoriasisatlas.org/en/explore. Accessed 11 Nov. 2026.

[4] Dimmock, Sarah, et al. “Global Epidemiology of Psoriasis: 2024 Update.” Global Psoriasis Atlas, 2024. https://www.globalpsoriasisatlas.org/uploads/attachments/cm4lhwxyi02onrlkqyq9u5tcw-global-epidemiology-of-psoriasis-2024-update-gene-to-clinic-2024-poster.pdf.

[5] Ramond, Anna, et al. “Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.” Dermatology and Therapy, vol. 15, no. 12, 2025, pp. 3765–3776. https://pmc.ncbi.nlm.nih.gov/articles/PMC12619857/.

[6] American Academy of Dermatology Association. “Are Triggers Causing Your Psoriasis Flare-Ups?” American Academy of Dermatology, https://www.aad.org/public/diseases/psoriasis/triggers/flares. Accessed 11 Nov. 2026.

[7] American Academy of Dermatology Association. “Psoriasis Clinical Guideline.” American Academy of Dermatology, https://www.aad.org/member/clinical-quality/guidelines/psoriasis. Accessed 11 Nov. 2026.

[8] National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Psoriasis.” National Institutes of Health, https://www.niams.nih.gov/health-topics/psoriasis. Accessed 11 Nov. 2026.

[9] Rome, Benjamin N., et al. “Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US.” JAMA Dermatology, vol. 161, no. 6, 2025, pp. 622–628. https://pmc.ncbi.nlm.nih.gov/articles/PMC12004245/.

[10] Armstrong, April W., et al. “Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey.” Dermatology, vol. 239, no. 4, 2023, pp. 621–634. https://pmc.ncbi.nlm.nih.gov/articles/PMC10357389/.

[11] National Psoriasis Foundation. “Psoriasis: Causes & Triggers.” National Psoriasis Foundation, updated 22 Jan. 2025, https://www.psoriasis.org/causes/.

[12] Gkini, Maria-Angeliki, et al. “Psoriasis in People With Skin of Color: An Evidence-Based Update.” International Journal of Dermatology, vol. 64, no. 4, 2025, pp. 667–677. https://pmc.ncbi.nlm.nih.gov/articles/PMC11931096/.

[13] Boey, Jonathan Yongwei, Jonathan Kantor, and Ellie Choi. “Interpreting the Global Burden of Disease 2023 Dermatology Estimates: Best Practices, Caveats, and Limitations for Researchers and Clinicians.” JAAD International, vol. 25, 18 Dec. 2025, pp. 78–80. https://pmc.ncbi.nlm.nih.gov/articles/PMC12914849/

[14] American Academy of Dermatology Association. “Psoriasis: Diagnosis and Treatment.” American Academy of Dermatology, https://www.aad.org/public/diseases/psoriasis/treatment/treatment. Accessed 11 Nov. 2026.